# US 2008/0188523 A1 · Pharmaceutical composition comprising, in combination, saredutant and paroxetine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188523 A1
- Document ID: US20080188523A1
- Status: Published application
- Kind: A1
- Application number: 11/830,304
- Filed: 2007-07-30
- Published: 2008-08-07
- Earliest claimed: 2007-02-07
- Assignees: Sanofi-Aventis
- Inventors: Guy Griebel; Caroline Cohen; Caroline Louis; Lisa Ann Arvanitis
- Web page: https://patentgrep.com/patent/US20080188523A1

## CPC

- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/15: Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/381: having five-membered rings
- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A subject-matter of the present invention is pharmaceutical compositions comprising, in combination, at least one active ingredient chosen front (S)-(−)-N-[4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from trans-(−)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluoropheny)piperidine and pharmaceutically acceptable salts thereof.

## Claims

### Claim 1

A combination comprising at least one active ingredient chosen from saredutant and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from paroxetine and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The combination according to claim 1, wherein said at least one active ingredient and said at least one second active ingredient are administered simultaneously, separately, or spread out over time.

### Claim 3 (depends on 2)

The combination according to claim 2, wherein said at least one active ingredient and said at least one second active ingredient are administered simultaneously.

### Claim 4 (depends on 2)

The combination according to claim 2, wherein said at least one active ingredient and said at least one second active ingredient are administered separately.

### Claim 5 (depends on 2)

The combination according to claim 2, wherein said at least one active ingredient and said at least one second active ingredient are administered spread out over time.

### Claim 6

A pharmaceutical composition comprising at least one active ingredient chosen from saredutant and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from paroxetine and pharmaceutically acceptable salts thereof in combination with at least one pharmaceutically acceptable excipient.

### Claim 7 (depends on 6)

The composition according to claim 6, wherein said at least one active ingredient and said at least one second active ingredient are administered simultaneously, separately, or spread out over time.

### Claim 8 (depends on 7)

The composition according to claim 7, wherein said at least one active ingredient and said at least one second active ingredient are administered simultaneously.

### Claim 9 (depends on 7)

The composition according to claim 7, wherein said at least one active ingredient and said at least one second active ingredient are administered separately.

### Claim 10 (depends on 7)

The composition according to claim 7, wherein said at least one active ingredient and said at least one second active ingredient are administered spread out over time.

### Claim 11

A method of treatment of a mood disorder in a patient comprising administering to the patient a therapeutically effective amount of at least one active ingredient chosen from saredutant and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from paroxetine and pharmaceutically acceptable salts thereof optionally in combination with one or more pharmaceutically acceptable excipients.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said at least one active ingredient and said at least one second active ingredient are administered simultaneously, separately or spread out over time.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said at least one active ingredient and said at least one second active ingredient are administered simultaneously.

### Claim 14 (depends on 12)

The method according to claim 12, wherein said at least one active ingredient and said at least one second active ingredient are administered separately.

### Claim 15 (depends on 12)

The method according to claim 12, wherein said at least one active ingredient and said at least one second active ingredient are administered spread out over time.

### Claim 16 (depends on 11)

The method according to claim 11, wherein the mood disorder is major depressive disorder.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the major depressive disorder is sexual dysfunctions associated with a major depressive disorder.

### Claim 18 (depends on 11)

The method according to claim 11, wherein the mood disorder is resistant depressive disorder.

### Claim 19 (depends on 11)

The method according to claim 11, wherein the mood disorder is dysthymic disorder.

### Claim 20 (depends on 11)

The method according to claim 11, wherein the mood disorder is depressive disorder not otherwise specified.

### Claim 21 (depends on 11)

The method according to claim 11, wherein the mood disorder is bipolar I disorder.

### Claim 22 (depends on 11)

The method according to claim 11, wherein the mood disorder is bipolar II disorder.

### Claim 23 (depends on 11)

The method according to claim 11, wherein the mood disorder is cyclothymic disorder.

### Claim 24 (depends on 11)

The method according to claim 11, wherein the mood disorder is bipolar disorder not otherwise specified.

### Claim 25 (depends on 11)

The method according to claim 11, wherein the mood disorder is mood disorder due to a general medical condition.

### Claim 26 (depends on 11)

The method according to claim 11, wherein the mood disorder is mood disorder induced by a substance.

### Claim 27 (depends on 11)

The method according to claim 11, wherein the mood disorder is mood disorder not otherwise specified.

### Claim 28 (depends on 11)

The method according to claim 11, wherein said at least one active ingredient is administered at a daily dosage of from about 10 mg to about 250 mg and said at least one second active ingredient is administered at a daily dosage of from about 5 mg to about 25 mg.

### Claim 29 (depends on 11)

The method according to claim 11, wherein said at least one active ingredient is administered at a daily dosage of about 100 mg and said at least one second active ingredient is administered at a daily dosage of about 20 mg.

### Claim 30 (depends on 11)

The method according to claim 11, wherein said at least one active ingredient is administered at a daily dosage of about 30 mg and said at least one second active ingredient is administered at a daily dosage of about 20 mg.

### Claim 31

A method of treatment of an anxiety disorder in a patient comprising administering to said patient a therapeutically effective amount of a combination of at least one active ingredient chosen from saredutant and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from paroxetine and pharmaceutically acceptable salts thereof optionally in combination with one or more pharmaceutically acceptable excipients.

### Claim 32 (depends on 31)

The method according to claim 31, wherein said at least one active ingredient and said at least one second active ingredient are administered simultaneously, separately or spread out over time.

### Claim 33 (depends on 32)

The method according to claim 32, wherein said at least one active ingredient and said at least one second active ingredient are administered simultaneously.

### Claim 34 (depends on 32)

The method according to claim 32, wherein said at least one active ingredient and said at least one second active ingredient are administered separately.

### Claim 35 (depends on 32)

The composition according to claim 32, wherein said at least one active ingredient and said at least one second active ingredient are administered spread out over time.

### Claim 36 (depends on 31)

The method according to claim 31, wherein the anxiety disorder is panic attack.

### Claim 37 (depends on 31)

The method according to claim 31, wherein the anxiety disorder is agoraphobia.

### Claim 38 (depends on 31)

The method according to claim 31, wherein the anxiety disorder is social phobia.

### Claim 39 (depends on 31)

The method according to claim 31, wherein the anxiety disorder is obsessive-compulsive disorder.

### Claim 40 (depends on 31)

The method according to claim 31, wherein the anxiety disorder is post-traumatic stress condition.

### Claim 41 (depends on 31)

The method according to claim 31, wherein the anxiety disorder is acute stress condition.

### Claim 42 (depends on 31)

The method according to claim 31, wherein the anxiety disorder is generalized anxiety disorder.

### Claim 43 (depends on 31)

The method according to claim 31, wherein the anxiety disorder is anxiety disorder induced by a substance.

### Claim 44 (depends on 31)

The method according to claim 31, wherein said at least one active ingredient is administered at a daily dosage of from about 10 mg to about 250 mg and said at least one second active ingredient is administered at a daily dosage of from about 5 mg to about 25 mg.

### Claim 45 (depends on 31)

The method according to claim 31, wherein said at least one active ingredient is administered at a daily dosage of about 100 mg and said at least one second active ingredient is administered at a daily dosage of about 20 mg.

### Claim 46 (depends on 31)

The method according to claim 31, wherein said at least one active ingredient is administered at a daily dosage of about 30 mg and said at least one second active ingredient is administered at a daily dosage of about 20 mg.
